Phase 2b Trial of a Na V 1.8 Inhibitor for Acute Pain

“From a clinical perspective, the published LTG-001 results in moderate-to-severe pain following abdominoplasty represent an important development in the treatment of acute pain, with the highest analgesic effect reported in a published industry-sponsored abdominoplasty trial. While opioids have historically been among the most effective options for treating acute pain, their associated risks underscore the importance of continued research into non-opioid approaches. These published results of LTG-001 add to the growing body of evidence supporting the investigation of novel, non-opioid mechanisms for pain management at a time when there remains significant focus on addressing the public health impact of opioid use.”

“This publication in the New England Journal of Medicine is a significant milestone for LTG-001. The publication of these findings adds to the growing scientific understanding of non-opioid approaches to pain management and comes at a time when there is broad recognition of the need for additional treatment options in the context of the ongoing opioid crisis.”

“We first reported a 'slow' sodium channel, responsible for hyperactivity in human pain-signaling neurons, in 1987. That channel was subsequently cloned and then named Nav1.8. Its essential role in pain signaling within peripheral nerve -- and lack of a role in the central nervous system -- made it a focus in attempts to develop non-addictive pain medications.”